Morepen Laboratories Limited has informed the Exchange regarding a press release dated February 23, 2026, titled "Morepen Bags ₹825 Crore Global Deal; Expands Into High-Growth CDMO Segment".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.9 pts more than Nifty Microcap 250 and 16.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Morepen Laboratories has won a multi-year Contract Development and Manufacturing Organization (CDMO) mandate worth approximately ₹825 crore (around USD 91 million) from a leading global pharmaceutical company. Supplies under the deal are expected to begin within the next 4–5 months, with execution scheduled to run through Q1 of the following financial year, subject to standard operational and regulatory clearances. The company describes this as one of the most significant single CDMO orders in its history, building on its four-decade API manufacturing experience. The deal leverages Morepen's internationally accredited facilities (USFDA, WHO-GMP, EU) and its ability to handle complex scale-ups for regulated markets. Management views CDMO as a natural extension of its API business and expects this win to open doors for larger, multi-year global opportunities.
Positive for shareholders — this sizable international order strengthens Morepen's revenue base, diversifies into higher-margin CDMO services, and validates its manufacturing credibility with global pharma majors. Stock sentiment is likely to improve, though actual earnings impact depends on smooth execution over the multi-year contract period.